No abstract available
Keywords:
Immunotherapy; Nivolumab; PD-L1; Renal-cell carcinoma; Treatment.
MeSH terms
-
Adult
-
Antineoplastic Agents, Immunological / therapeutic use*
-
Carcinoma, Medullary / immunology
-
Carcinoma, Medullary / pathology
-
Carcinoma, Medullary / therapy*
-
Carcinoma, Renal Cell / immunology
-
Carcinoma, Renal Cell / pathology
-
Carcinoma, Renal Cell / therapy*
-
Chemoradiotherapy, Adjuvant / methods
-
Female
-
Humans
-
Kidney Neoplasms / immunology
-
Kidney Neoplasms / pathology
-
Kidney Neoplasms / therapy*
-
Lymph Node Excision
-
Lymphatic Metastasis / pathology
-
Nephrectomy
-
Nivolumab / therapeutic use*
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors
-
Treatment Outcome
Substances
-
Antineoplastic Agents, Immunological
-
PDCD1 protein, human
-
Programmed Cell Death 1 Receptor
-
Nivolumab